ArticleJournal of diabetes research2026
Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
GLP-1 receptor agonists (GLP-1RAs) are extensively used in treating Type 2 diabetes due to their therapeutic benefits. However, clinical reports have highlighted adverse events, particularly the underexplored association with tumor development. This study investigates GLP-1RA-related adverse events, focusing on tumorigenic risks, using data from the FDA Adverse Event Reporting System (FAERS). FAERS data from Q1 2005 to Q4 2023 were analyzed using the proportional reporting ratio (PRR) method to identify GLP-1RA-associated adverse events. Detailed analyses examined event distribution across genders, ages, and body weights, with an emphasis on tumor-related risks in vulnerable subpopulations. A total of 195,250 GLP-1RA-related adverse event reports were identified, spanning 25 system organ classes (SOCs). The most reported SOCs were gastrointestinal disorders (n = 110,451, PRR 2.44), investigative findings (n = 80,126, PRR 2.46), and metabolism and nutrition disorders (n = 25,236, PRR 2.21). Notably, 7457 cases involved benign, malignant, and unspecified tumors (PRR 0.5). Further analysis revealed that the risk of GLP-1RA-associated tumorigenesis varied by age, sex, and weight, suggesting that tumorigenesis risk differed in specific subpopulations. These findings underscore the need for vigilance regarding GLP-1RA-related adverse events, particularly tumor risks in specific subgroups. Clinicians should consider patient-specific factors, such as age, gender, and body weight, to ensure safe and effective GLP-1RAs therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.